Comparison of granisetron and ramosetron for the prevention of nausea and vomiting after thyroidectomy.

[1]  A. Harris,et al.  A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response , 2004, Cancer Chemotherapy and Pharmacology.

[2]  Y. Fujii,et al.  Granisetron, Droperidol, and Metoclopramide for Preventing Postoperative Nausea and Vomiting After Thyroidectomy , 1999, The Laryngoscope.

[3]  H. Toyooka,et al.  Prophylactic antiemetic therapy with granisetron in women undergoing thyroidectomy. , 1998, British journal of anaesthesia.

[4]  G. Andry,et al.  Antiemetic effect of subhypnotic doses of propofol after thyroidectomy. , 1996, British journal of anaesthesia.

[5]  野田起一郎.  Clinical evaluation of YM060 against nausea and vomiting induced by anticancer drugs (phase ffl study) , 1996 .

[6]  A. Nishida,et al.  Comparative study of the affinities of the 5-HT3 receptor antagonists, YM060, YM114 (KAE-393), granisetron and ondansetron in rat vagus nerve and cerebral cortex , 1995, Neuropharmacology.

[7]  D. McTavish,et al.  Granisetron , 1994, Drugs.

[8]  P. White,et al.  Postoperative Nausea and Vomiting: Its Etiology, Treatment, and Prevention , 1992, Anesthesiology.

[9]  W. Soudijn,et al.  The concept of selectivity in 5-HT receptor research. , 1990, European journal of pharmacology.

[10]  P. Ewalenko,et al.  Alizapride in the prevention of post-thyroidectomy emetic sequelae , 1990 .

[11]  G. Sanger,et al.  The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. , 1988, British Journal of Cancer.